Cryotherapy is a minimally invasive procedure that aims to destroy tumor cells by exposing them to extremely low temperatures (− 40 to − 50 °C). Cryotherapy induces cell death through several ...

With smaller radiation beams, intensity-modulated radiation therapy “takes precision to the next level” for patients with prostate, an expert told CURE®. Intensity-modulated radiation therapy (IMRT) — ...

People with low- and intermediate-risk prostate cancer treated with either of two types of contemporary radiation therapy—proton beam therapy or intensity modulated radiation therapy (IMRT)—achieved ...

Patient-reported quality of life (QoL) was similar between proton beam therapy (PBT) and intensity-modulated radiation therapy (IMRT) among men with localized prostate cancer, the randomized PARTIQoL ...

People with low- and intermediate-risk prostate cancer treated with either of two types of contemporary radiation therapy - proton beam therapy or intensity modulated radiation therapy (IMRT) - ...

Proton therapy reduces radiation to nontargeted tissues, but for men with localized prostate cancer that may not translate to better outcomes, according to early results from the large prospective ...

Preliminary data from a dose-escalation phase 1 study with HP518, an AR PROTAC degrader: Safety, tolerability, pharmacokinetics (PK), and first assessment of anti-tumor activity in patients (Pts) with ...

The phase 3 NRG GU-005 trial did not show a DFS benefit for SBRT vs IMRT in intermediate-risk prostate cancer, but SBRT decreased rectal toxicity. Stereotactic body radiation therapy (SBRT) preserves ...

Proton beam therapy continues to generate significant interest — and controversy — in prostate cancer. About 45 cancer centers in the US offer proton therapy to treat a variety of cancers, including ...

For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to ...

Proton beam therapy does not improve the patient-reported outcome of bowel function compared with IMRT. Bowel side effects do not differ between patients with localized prostate cancer who receive ...